Evidence map›Paper›PMID 27819326›Full record

ArticleScientific reports2016

Insights into a novel nuclear function for Fascin in the regulation of the amino-acid transporter SLC3A2.

Amine Saad, Krikor Bijian, Dinghong Qiu, Sabrina Daniela da Silva, Maud Marques, Chia-Hao Chang, Hassan Nassour, Dindial Ramotar, Sambasivarao Damaraju, John Mackey and 3 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
0.2field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. IntracellularFrontiers in veterinary science · 2021
    Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

Amine SaadDepartments of Medicine, Oncology, Pharmacology and Therapeutics , Segal Cancer Centre and Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, 3755 Cote-Ste Catherine, Montreal, Quebec, H3T 1E2, Canada.
Krikor BijianDepartments of Medicine, Oncology, Pharmacology and Therapeutics , Segal Cancer Centre and Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, 3755 Cote-Ste Catherine, Montreal, Quebec, H3T 1E2, Canada.
Dinghong QiuDepartments of Medicine, Oncology, Pharmacology and Therapeutics , Segal Cancer Centre and Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, 3755 Cote-Ste Catherine, Montreal, Quebec, H3T 1E2, Canada.
Sabrina Daniela da SilvaDepartments of Medicine, Oncology, Pharmacology and Therapeutics , Segal Cancer Centre and Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, 3755 Cote-Ste Catherine, Montreal, Quebec, H3T 1E2, Canada.
Maud MarquesDepartments of Medicine, Oncology, Pharmacology and Therapeutics , Segal Cancer Centre and Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, 3755 Cote-Ste Catherine, Montreal, Quebec, H3T 1E2, Canada.
Chia-Hao ChangDepartments of Medicine, Oncology, Pharmacology and Therapeutics , Segal Cancer Centre and Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, 3755 Cote-Ste Catherine, Montreal, Quebec, H3T 1E2, Canada.
Hassan NassourMaisonneuve-Rosemont Hospital, Research Center, University of Montreal, Immunology and Oncology, Montreal, Quebec, H1T 2M4, Canada.
Dindial RamotarMaisonneuve-Rosemont Hospital, Research Center, University of Montreal, Immunology and Oncology, Montreal, Quebec, H1T 2M4, Canada.
Sambasivarao DamarajuDepartments of Laboratory Medicine and Pathology, University of Alberta, Cross Cancer Institute, 11560 University Avenue, Edmonton, Alberta, T6G 1Z2, Canada.
John MackeyDepartment of Oncology, University of Alberta, Cross Cancer Institute, 11560 University Avenue, Edmonton, Alberta, T6G 1Z2, Canada.
Tarek BismarDepartments of Pathology &Laboratory Medicine and Oncology, Southern Alberta Cancer Institute, University of Calgary, Alberta, Canada.
Michael WitcherDepartments of Medicine, Oncology, Pharmacology and Therapeutics , Segal Cancer Centre and Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, 3755 Cote-Ste Catherine, Montreal, Quebec, H3T 1E2, Canada.
Moulay A Alaoui-JamaliDepartments of Medicine, Oncology, Pharmacology and Therapeutics , Segal Cancer Centre and Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, 3755 Cote-Ste Catherine, Montreal, Quebec, H3T 1E2, Canada.
Jewish General Hospital · CAUniversity of Alberta · CAHôpital Maisonneuve-Rosemont · CAMcGill University · CAUniversité de Montréal · CAUniversity of Calgary · CA

Funding

CIHR
6 · The paper itself

Abstract

Fascin 1 (FSCN1) is a cytoskeleton-associated protein recognized to function primarily in the regulation of cytoskeleton structure and formation of plasma membrane protrusions. Here we report a novel nuclear function for Fascin 1. Biochemical studies and genome wide localization using ChIP-seq identified phosphorylated Fascin 1 (pFascin) in complexes associated with transcription and that it co-localizes with histone H3 Lys4 trimethylation (H3K4me3) on chromatin. Gene expression profiling identified genes affected by Fascin 1 including SLC3A2, a gene encoding for a plasma membrane transporter that regulates intracellular amino acid levels. RbBP5, a subunit of the H3K4 histone methyltransferase (HMT) complex was found to interact with Fascin 1 supporting its role in H3K4me3 establishment at target genes. Moreover, we show that changes to SLC3A2 levels affect amino acid-mediated mTORC1 activation. These results reveal that Fascin 1 has a yet undiscovered nuclear function as an epigenetic modulator of genes essential for amino acid metabolism.

Indexed as

Gene ExpressionGene Expression RegulationBreast NeoplasmsCarrier ProteinsCell Line, TumorCell NucleusDNA-Binding ProteinsFusion Regulatory Protein 1, Heavy ChainHEK293 CellsHistonesHumansMicrofilament ProteinsNuclear ProteinsPhosphorylationTOR Serine-Threonine KinasesTranscriptomeCarrier ProteinsDNA-Binding ProteinsFSCN1 protein, humanFusion Regulatory Protein 1, Heavy ChainHistonesMicrofilament ProteinsMTOR protein, humanNuclear ProteinsRBBP5 protein, humanSLC3A2 protein, humanTOR Serine-Threonine Kinases

Identifiers

PMID27819326
PMCPMC5098188
OpenAlexW2556884992

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.